Edoxaban

Generic Name
Edoxaban
Brand Names
Lixiana, Savaysa, Roteas
Drug Type
Small Molecule
Chemical Formula
C24H30ClN7O4S
CAS Number
480449-70-5
Unique Ingredient Identifier
NDU3J18APO
Background

Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to reduce the risk of stroke and systemic em...

Indication

Edoxaban is indicated for reducing the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF). However, it should not be used in patients with creatinine clearance (CrCL) > 95 mL/min because of increased risk of ischemic stroke compared to warfarin at the highest dose studied (60 mg). It is also indicated for the tr...

Associated Conditions
Deep Vein Thrombosis, Pulmonary Embolism, Stroke, Systemic Embolism
Associated Therapies
-
Clinical Trials
Related News

Edoxaban in Peripheral Arterial Disease

First Posted Date
2013-03-01
Last Posted Date
2019-02-26
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
203
Registration Number
NCT01802775
Locations
🇧🇪

Edgem, Edegem, Belgium

A Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty

First Posted Date
2010-08-13
Last Posted Date
2019-03-05
Lead Sponsor
Daiichi Sankyo Co., Ltd.
Target Recruit Count
610
Registration Number
NCT01181167

A Phase 3 Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty

First Posted Date
2010-08-13
Last Posted Date
2019-03-05
Lead Sponsor
Daiichi Sankyo Co., Ltd.
Target Recruit Count
716
Registration Number
NCT01181102
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy